We’ve awarded $5.3m to enable 12 world-class researchers around Australia

Cancer Council NSW

Cancer Council NSW is excited to announce over $5.3 million in funding for new cancer research projects. Thanks to your support, we’re able to award funding to 12 world-class cancer research projects.

Without the support of such an amazing community of fundraisers and donors, this would simply not have been possible. Your help ensures that we’re here for life.

These eminent and up-and-coming cancer researchers are tackling cancer by improving patient diagnosis and innovating therapy techniques, across a range of cancers, including common cancers like prostate and breast.

Funding is awarded through an independent process with projects assessed on their scientific merit and potential impact for the community.

Resolving prostate cancer: Elucidating the epigenetics of tumour microenvironment cells to advance understanding of disease aetiology and improve patient diagnosis, Dr Ruth Elizabeth Pidsley, The Garvan Institute of Medical Research

Pan-cancer assessment of sensitivity towards novel selective oncogenic JNK inhibitors, Dr Sharissa Louise Latham, The Garvan Institute of Medical Research

Exploiting a new epigenetic regulatory mechanism for sustaining leukaemia-initiating activity, Dr Jenny Yingzi Wang, University of Sydney

Discovery and validation of a diagnostic and prognostic blood-based biomarker for human endometrial cancer, Prof Pradeep Tanwar, University of Newcastle

Targeting aggressive cancers that use the Alternative Lengthening of Telomeres (ALT) mechanism, Assoc Prof Karen Lee MacKenzie, University of Sydney

Targeting pancreatic cancer (PC) via anti-fibrotic NID2 therapy and Gemcitabine/Abraxane chemotherapy treatment: stratifying PC therapy, Paul Timpson, The Garvan Institute of Medical Research

Defining the circulating genome of high-risk plasma cell disorders to improve risk stratification and clinical management, Dr Sridurga Mithraprabhu, Monash University

Improving our understanding of the oncogenic signalling-metabolism nexus to design better treatments for pancreatic cancer, Associate Professor Nigel Turner, University of New South Wales

Advanced pre-clinical evaluation of sphingosine kinase 1-targeting agents as a therapy for acute myeloid leukaemia, Prof Stuart Maxwell Pitson, University of South Australia

Creating the Next Generation in Radiotherapy Imaging with Carbon Nanotube Sources and Photon Counting Detectors, Dr Owen Dillon, University of Sydney

MARCH5 is a master regulator of BCL2 proteins and a potential anti-cancer drug target, Dr Mark F van Delft, The Walter and Eliza Hall Institute of Medical Research

Predicting clinical response to breast cancer therapy – the immune signature approach, Professor Barbara D Fazekas de St Groth, University of Sydney

Without the support of our incredible community, we wouldn’t be able to fund research and grow our collective understanding of how to better diagnose and treat cancer.

We’d like to extend an additional thanks to the Box Rallies community, who each year, thanks to their fundraising support ensure that we can fund many of these projects.

Funding the next cancer research breakthrough takes all of us.

/Public Release. View in full here.